We are a medical communications company with a passion for developing high-quality content. We write & design content for healthcare professionals and patients in a variety of therapeutic areas. If you like our podcast, please take the time to rate it and subscribe. See our website for more information, video capsules, and podcasts at: https://www.impactmedicom.com.
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
32%
Guest openness
Selective
Sign up to generate a grounded pitch for IMPACT Medicom.
Signup to Generate a PitchWe are a medical communications company with a passion for developing high-quality content. We write & design content for healthcare professionals and patients in a variety of therapeutic areas. If you like our podcast, please take the time to rate it and subscribe.
Recent episodes include "Canadian Hematology Consensus Group: RR FL Consensus Paper Discussion" (19 August 2026, 13 minutes), "Introduction to the Canadian Hematology Consensus Group (CHCG)" (29 May 2026, 20 minutes), and "Double-Exposed CLL/SLL: A Canadian Perspective" (2 December 2025, 23 minutes).
IMPACT Medicom publishes roughly every few months, with episodes averaging 22 minutes across 57 episodes.
Booking probability for IMPACT Medicom is 32%, and the host is rated Selective on guests. IMPACT Medicom requires a Pod Score of 80 or higher. IMPACT Medicom's contact route on record: verified email.
The strongest fits for IMPACT Medicom are Health & Wellness Services and Doctors & Physicians. IMPACT Medicom has a science audience.
IMPACT Medicom is a science podcast with 57 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
IMPACT Medicom
The Canadian Hematology Consensus Group, or CHCG, is a national collaboration of Canadian hematologists and healthcare professionals dedicated to improving patient care through the development of National consensus...
IMPACT Medicom
Dr. Carolyn Owen, Chair of the Canadian Hematology Consensus Group (CHCG), introduces the CHCG and discusses its mission to develop evidence-based Canadian consensus recommendations in areas of unmet need in hematology...
IMPACT Medicom
In this episode with Dr Robert Puckrin, we discuss the unmet needs of double-exposed patients with CLL/SLL, as well as the current and novel treatments that can address this gap. Our guest Dr. Puckrin is a Hematologist...
IMPACT Medicom
In this podcast episode, Dr. Dimitrios Coutsinos describes a video capsule series involving three educational videos of lung resections using minimally invasive video-assisted thoracic surgery (VATS) following...
IMPACT Medicom
In this podcast episode, we discuss clinical trial updates in chronic lymphocytic leukemia from the 2025 European Hematology Association annual congress in Milan, Italy and the 18th International Conference on Malignant...
IMPACT Medicom
(FRENCH) In this podcast episode, which follows this introduction in French, Dr Christopher Lemieux summarizes a paper by Dr Abramson, et al. on the management of Peripheral Neuropathy Associated with Brentuximab...
IMPACT Medicom
In this podcast episode, Dr. Michael Chu discusses the management of peripheral neuropathy associated with the use of brentuximab vedotin for the first-line treatment of classical Hodgkin Lymphoma. Our Guest Dr. Michael...
IMPACT Medicom
In this podcast episode, Dr. Versha Banerji, a Canadian hematologist from Manitoba and Dr. Jennifer Brown, an internationally renowned hematologist from the United States, discuss data on the treatment of CLL presented...
IMPACT Medicom
In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL. Our Guest: Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist...
IMPACT Medicom
In this podcast episode, three of Canada’s top hematologists discuss data on the treatment of CLL presented at the European Hematology Association (or EHA) meeting in Madrid, Spain. The discussion involves an analysis...
IMPACT Medicom
In this episode of our podcast, recorded at the European Hematology Association (EHA) meeting in Madrid, Spain, we discuss updated results of the BGB-11417-101 trial with Dr. Stephen Opat. The BGB-11417-101 trial...
IMPACT Medicom
In this episode, Dr. Barbara Melosky discusses cutting edge approaches to the treatment of Lung Cancer, including the use of artificial intelligence and novel therapeutic approaches such as cancer vaccines and new...
IMPACT Medicom
Welcome to our podcast episode on diagnostic, prognostic and predictive biomarkers for the treatment of upper GI cancers. In this episode, Dr Brezden-Masley (medical oncologist) and Dr Streutker (pathologist) discuss...
IMPACT Medicom
In this podcast episode, Dr. Evan Lipson discusses the use of immunotherapy for patients with skin cancer who have had a kidney transplant. Our guest: Dr. Lipson is an internationally-recognized skin cancer and...
IMPACT Medicom
In this video capsule, Dr. Mark Taylor discusses the surgical implications for the treatment of cSCC. This podcast episode is best viewed alongside the slides, which can be found in the video capsule version...
IMPACT Medicom
In this podcast episode, Dr. Rami Kotb and Dr. Donna Reece discuss results of the CMRG Isa-CYBORD trial presented at the ASH 2023 meeting, and the implications of the results for Canadian clinical practice. Our Guests...
IMPACT Medicom
In this episode of our podcast, recorded at the American Society of Hematology (ASH) in San Diego, California, we discuss updated results of the ALPINE trial with Dr. Jennifer Brown. The ALPINE trial examined the...
Episode #5
In this video capsule series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This fifth episode of the series was recorded live from ESMO...
Episode #1
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar...
IMPACT Medicom
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar...
Recent guests on IMPACT Medicom. Study who booked and why before you pitch.
award-winning speaker, bestselling author, and voice in inclusive leadership, diversity, equity, and inclusion
Senior Specialist, Audio Applications & Support Group - US & Canada, WonderBuilt Restoration and Construction
Senior Manager of Market Research Insights & Intelligence, Queen Mary University of London
Professor of Medicine in the Division of Rheumatology, Epidemiology and Biostatistics at the University of Western Ontario, University of Western Ontario
PitchCentric classifies IMPACT Medicom under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ
